Studies find that multiple purchases by C-level executives signal strong annualized returns.
|
Sionna Therapeutics, Inc. – SYM: SION Recent Price: $19.66
Insider Action: 6 insiders buy $62 mil in shares Description: Sionna Therapeutics is a biopharmaceutical company that develops treatments for cystic fibrosis (CF). They are clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein to deliver clinically meaningful benefit to CF patients. SION's goal is to deliver differentiated medicines for people living with CF that can restore CFTR function to as close to normal as possible by directly stabilizing CFTR’s nucleotide-binding domain 1 (“NBD1”). The company was founded in 2019 and is based in Waltham, Massachusetts. |
Friedman Industries, Incorporated – SYM: FRD Recent Price: $16.87
Insider Action: 5 insiders buy $742K in shares Description: Friedman Industries, Incorporated engages in the manufacture and processing of steel products in the United States. It operates in two segments, Flat-Roll Products and Tubular Products. The Flat-Roll Product segment is involved in the conversion of steel coils into flat sheet and plate steel cut to customer specifications and reselling steel coils, as well as provision of process and storage services for customer-owned coils on a fee basis. The segment offers its products and services to steel distributors and customers manufacturing steel products, such as steel buildings, railroad cars, barges, tanks and containers, trailers, component parts, and other fabricated steel products. The Tubular Product segment manufactures line and oil country pipes, as well as pipes for structural applications. This segment sells its tubular products principally to steel and pipe distributors through its own sales force. The company was incorporated in 1965 and is based in Longview, Texas. |
Two Major Trends to Survive in Options Trading
Bloomberg just reported that more than HALF of all trading in U.S. stocks is made outside the country’s exchanges, like dark pools.
“For the first time on record, the majority of all trading in US stocks is now consistently occurring outside the country’s exchanges, according to data compiled by Bloomberg.”
In fact, the off-exchange activity is on course to account for a record 51.8% of traded volume in January.
Click here to claim FREE dark pool alerts now.
|
Perspective Therapeutics, Inc. – SYM: CATX Recent Price: $3.04
Insider Action: 4 insiders buy $302K in shares Description: Perspective Therapeutics, Inc., together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma. Perspective Therapeutics, Inc. has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is headquartered in Seattle, Washington. |
|
|
Our mailing address is:
DC2 Publishing LLC
4260 NW 1st Avenue Suite # 55
Boca Raton, FL 33431 - 4264 Daily Insider Trades
Copyright © 2024 DC2 Publishing LLC, All rights reserved.
You're receiving this email as part of your subscription to Daily Insider Trades. For more information about our privacy practices, please review our Privacy Policy or our Terms of Use.
|
Click here to unsubscribe |
|
|
|
